What is AngioScore?
Headquartered in Fremont, California, AngioScore is a privately held endovascular company dedicated to improving patient outcomes through advanced engineering. The company is best known for its flagship AngioSculpt Scoring Balloon Catheter, a device that integrates nitinol-scoring elements with traditional balloon technology. This unique design provides focal concentrations of dilating force, effectively minimizing balloon slippage and enhancing the luminal expansion of stenotic arteries. By addressing the clinical challenge of geographic miss, AngioScore has established itself as a vital player in the interventional cardiology market, providing physicians with the precision tools necessary for complex vascular procedures.
How much funding has AngioScore raised?
AngioScore has raised a total of $12M across 1 funding round:
Private Equity
$12M
Private Equity (2012): $12M with participation from Saints capital, QuestMark Partners, Pelion Venture Partners, California Technology Ventures, LLC, and Telegraph Hill Partners
Key Investors in AngioScore
Saints Capital
Saints Capital is a pioneering investment firm specializing in GP-led transactions within the venture secondary market, providing liquidity solutions for private companies.
QuestMark Partners
QuestMark Partners is an expansion-stage investment firm that partners with management teams to build market-leading companies in sectors such as healthcare IT and tech-enabled services.
Pelion Venture Partners
Pelion Venture Partners manages a diverse portfolio of funds, focusing on providing investment solutions and strategic support to institutional and individual clients.
What's next for AngioScore?
With the recent influx of capital, AngioScore is well-positioned to accelerate its commercialization efforts and deepen its penetration into the competitive life science market. The strategic nature of this financing suggests a focus on scaling manufacturing capabilities and potentially expanding the clinical applications of the AngioSculpt platform. As the company moves into its next phase of growth, it will likely prioritize the integration of its technology into broader clinical workflows, ensuring that its scoring balloon catheters remain the standard of care for practitioners treating arterial disease. The continued support from institutional investors signals strong confidence in the company's long-term value proposition and its ability to navigate the rigorous regulatory and commercial demands of the medical device industry.
See full AngioScore company page
